Patrickr Oneil News Today

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday. IONS has been the subject of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and set a […]

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one […]

StockNews.com upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday. A number of other equities research analysts have also recently commented on the company. Royal Bank of Canada reissued an outperform rating and issued a $65.00 price objective […]

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday. A number of other brokerages also recently issued reports on IONS. Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $45.00 to $50.00 and […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Patrick R. O’neil sold 20,825 shares of the business’s stock in a transaction dated Tuesday, December 26th. The stock was sold at an average price of $51.46, for a total value of $1,071,654.50. Following the transaction, the executive vice president now owns 40,355 shares of the […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) – Investment analysts at William Blair cut their Q3 2023 earnings estimates for Ionis Pharmaceuticals in a report issued on Wednesday, August 9th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.95) per share for the quarter, down from their previous forecast […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned a consensus recommendation of “Hold” from the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 8,690,000 shares, a growth of 33.3% from the May 31st total of 6,520,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 8,690,000 shares, a growth of 33.3% from the May 31st total of 6,520,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio […]

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 8,690,000 shares, an increase of 33.3% from the May 31st total of 6,520,000 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is […]